Biotech
Graphite Bio
Graphite Bio raises $238M Series B at $1B valuation
$238M
Total Raised
Series B
Latest Round
2019
Founded
150+
Employees
279 East Grand Avenue, South San Francisco, CA 94080
1 min read
Quick Facts
Valuation
$1B
Latest Round Size
$238M
Latest Round Date
April 2024
Graphite Bio: Series B Funding Round
Graphite Bio has successfully raised $238M in Series B funding, reaching a valuation of $1B.
Company Overview
Precision genetic medicines
Funding Details
The Series B round was led by ARCH Venture Partners, with participation from Vida Ventures, Norwest Venture Partners, Samsara BioCapital.
Company Information
- Headquarters: 279 East Grand Avenue, South San Francisco, CA 94080
- Founded: 2019
- Employees: 150+
- Category: Biotech
Investment
Graphite Bio plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- ARCH Venture Partners: Verified investor in Series B
- Vida Ventures: Verified investor in Series B
- Norwest Venture Partners: Verified investor in Series B
- Samsara BioCapital: Verified investor in Series B
Key Investors
ARCH Venture Partners
Lead Investor
Verified investor in Series B
Vida Ventures
Investor
Verified investor in Series B
Norwest Venture Partners
Investor
Verified investor in Series B
Samsara BioCapital
Investor
Verified investor in Series B
About the Author
Editorial Team
Curated funding news from verified sources
Related Company Reports
Biotech
Orna Therapeutics
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Emma Rodriguez
Oct 23, 2025
0 min read•$251M Series B
Biotech
Forge Biologics
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Sarah Kim
Oct 23, 2025
0 min read•$120M Series C
Biotech
Vir Biotechnology
Vir Biotechnology Raises $250M
Clinical-stage immunology company developing treatments for infectious diseases including COVID-19, hepatitis B, and influenza
Sarah Kim
Oct 23, 2025
0 min read•$250M